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Molecular analysis of pediatric brain tumors
identifies microRNAs in pilocytic
astrocytomas that target the MAPK and
NF-κB pathways
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Abstract
Introduction: Pilocytic astrocytomas are slow-growing tumors that usually occur in the cerebellum or in the midline
along the hypothalamic/optic pathways. The most common genetic alterations in pilocytic astrocytomas activate the
ERK/MAPK signal transduction pathway, which is a major driver of proliferation but is also believed to induce
senescence in these tumors. Here, we have conducted a detailed investigation of microRNA and gene expression,
together with pathway analysis, to improve our understanding of the regulatory mechanisms in pilocytic astrocytomas.
Results: Pilocytic astrocytomas were found to have distinctive microRNA and gene expression profiles compared to
normal brain tissue and a selection of other pediatric brain tumors. Several microRNAs found to be up-regulated in
pilocytic astrocytomas are predicted to target the ERK/MAPK and NF-κB signaling pathways as well as genes
involved in senescence-associated inflammation and cell cycle control. Furthermore, IGFBP7 and CEBPB, which are
transcriptional inducers of the senescence-associated secretory phenotype (SASP), were also up-regulated together
with the markers of senescence and inflammation, CDKN1A (p21), CDKN2A (p16) and IL1B.
Conclusion: These findings provide further evidence of a senescent phenotype in pilocytic astrocytomas. In addition,
they suggest that the ERK/MAPK pathway, which is considered the major driver of these tumors, is regulated not only
by genetic aberrations but also by microRNAs.
Keywords: Grade I astrocytoma, Children, Senescence-associated secretory phenotype (SASP), miR-146a, miR-155,
Neuroinflammation, KIAA1549-BRAF
Introduction
Pilocytic astrocytomas (WHO grade I) are the most
common central nervous system tumors in the 5 to
19 year age group. They are cystic, well-circumscribed
tumors, which rarely progress and can usually be re-
moved using surgery [9]. This accounts for their having
a more favourable prognosis than diffuse and other in-
filtrative astrocytomas [39]. Molecular studies on pilo-
cytic astrocytomas have identified recurrent BRAF gene
fusions and other alterations that activate the ERK/
MAPK signal transduction pathway [15, 27, 56]. Acti-
vated ERK/MAPK signaling is believed to drive cellu-
lar proliferation and then to trigger senescence, giving
rise to the indolent phenotype of pilocytic astrocyto-
mas [24, 42].
MicroRNAs are short RNA molecules that modulate
gene expression post-transcriptionally by repressing
translation or degrading the mRNA transcript [26].
They regulate numerous biological processes including
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cell proliferation and differentiation, and have major
roles in embryogenesis, including brain and spinal cord
development and neurogenesis [13, 41]. Many micro-
RNAs are involved in the initiation and progression of
cancer [3, 37], and recent studies of pediatric brain tu-
mors have identified tumor-specific microRNA signa-
tures [5, 21, 38].
To further our knowledge of the molecular drivers of
pilocytic astrocytomas, we conducted a detailed investiga-
tion of microRNA and gene expression in these tumors,
and characterised the findings by pathway analysis. Our
results revealed a distinctive microRNA and gene expres-
sion profile in pilocytic astrocytoma compared to other
pediatric brain tumors. We found that many predicted tar-
gets of up-regulated microRNAs in pilocytic astrocytomas
are known regulators of the ERK/MAPK and NF-κB path-
ways. These findings suggest an important modulatory
role for microRNAs in critical pathways involved in pilo-
cytic astrocytomas.
Materials and methods
Tumor samples and controls
miRNA and mRNA profiling was performed on a range
of fresh frozen brain tumor samples (the test cohort)
from 57 children, aged 1–16 years, and on 7 normal
adult brain controls (4 frontal lobe and 3 cerebellum,
Biochain) (Table 1a). A further 13 pediatric brain tumor
samples were used as a validation cohort (Table 1b).
Tumors were classified using criteria defined by the
World Health Organization (WHO) [36]. Access to
samples and clinical data complied with Local Research
Ethics Committee (LREC) regulations: Great Ormond
Street Hospital LREC reference number 05/Q0508/153.
All the test pilocytic astrocytomas were shown previ-
ously to contain the KIAA1549-BRAF gene fusion [32].
The BRAF V600E mutation was also examined in the
high-grade astrocytomas in the test cohort. KIAA1549-
BRAF fusion and the BRAF V600E mutations were also
tested in the validation cohort using PCR according to
published protocols [32, 45].
MicroRNA and gene expression arrays
MicroRNA expression was profiled in the test tumor co-
hort and the normal brain controls using Illumina Micro-
RNA Expression Arrays (MI-v2). This system screens
1,146 known and putative microRNAs including 97 % of
microRNAs in miRBase (Release 12.0). Gene expression
profiles were obtained for the same tumors and controls
using the Illumina HumanHT-12_v3 Beadchip system.
RNA was extracted from the samples using TRIzol (Invi-
trogen) and eluted into RNAse-free water using the
RNeasy mini kit (Qiagen). cDNA was synthesized using
random hexamers and the SuperScript First-Strand cDNA
synthesis system (Invitrogen). Hybridization and scanning
were performed in-house at the Barts and The London
Genome Centre.
Statistical analysis
The microRNA and gene expression-averaged tumor
profiles were compared to normal adult brain controls
using GenomeStudio and GeneSpring Multi-Omic Ana-
lysis v12.1 software. Data were subjected to threshold-
ing, log transformation (log2), normalization (quantile)
and baseline transformation (median to all samples).
Normalized data of microRNA and gene expression are
shown in Additional file 1: Table S1 and Additional file 2:
Table S2. All data were deposited in NCBI’s Gene Expres-
sion Omnibus [12] (http://www.ncbi.nlm.nih.gov/geo) and
are accessible through GEO accession number GSE42658.
Differential expression was defined as fold change (FC) > 2
with FDR corrected (Benjamini Hochberg) p-values < 0.05.
Unsupervised hierarchical clustering (Euclidean method),
was performed on both the microRNA and mRNA expres-
sion data. The differentially expressed microRNAs and
genes are listed in Additional file 3: Table S3 and Additional
file 4: Table S4 for tumor groups with more than three
samples.
Pathway analysis
Ingenuity Pathway Analysis (Ingenuity Systems Inc.,
Redwood City, USA) was used to identify over-represented
pathways for significantly differentially expressed genes in
pilocytic astrocytomas. The significance value associated
with the functional analysis is expressed as a p-value calcu-
lated by comparing the number of differentially expressed
genes that participate in a given function or pathway, rela-
tive to the total number of occurrences of these proteins
in all functional/pathway annotations stored in Ingenu-
ity Pathway Knowledge Base. Multiple-testing corrected
p-values were calculated using the Benjamini-Hochberg
method. For each functional annotation, a statistical
quantity is calculated called the regulation z-score. The
purpose of the z-score is to identify increased or decreased
biological functions that are likely implicated by the ob-
served gene expression changes. Hence, the p-values
measure the observed and predicted regulated gene sets,
and the z-score assesses the match of the observed and
predicted up/down regulation patterns. For this study,
we only considered a predicted activation/inhibition
status as significant if the p-value was < +/−0.05 and the
z-score > 2.0 or < 2.0 respectively.
Taqman microRNA assays
TaqMan miRNA assays were used to validate differen-
tially expressed microRNAs of interest. Control micro-
RNAs RNU48 and miR-423-3p were tested for stability
over all tumors and miR-423-3p was selected as the
most stable control. Hence all samples were normalized
Jones et al. Acta Neuropathologica Communications  (2015) 3:86 Page 2 of 13
Table 1 Pediatric tumor cohorts
Tumor Pathology Grade Location Sex Age BRAF status
a.
PGNT Papillary glioneuronal I Frontal lobe M 14 nd
PA1 Pilocytic astrocytoma I Posterior fossa F 16 KIAA1549-BRAF exon 16-exon 9
PA2 Pilocytic astrocytoma I Posterior fossa M 12 KIAA1549-BRAF exon 16-exon 9
PA3 Pilocytic astrocytoma I Posterior fossa M 14 KIAA1549-BRAF exon 16-exon 9
PA5 Pilocytic astrocytoma I Posterior fossa F 3 KIAA1549-BRAF exon 16-exon 9
PA6 Pilocytic astrocytoma I Cerebellum F 8 KIAA1549-BRAF exon 15-exon 9
PA7 Pilocytic astrocytoma I Cerebellum M 1 KIAA1549-BRAF exon 16-exon 11
PA8 Pilocytic astrocytoma I Cerebellum M 1 KIAA1549-BRAF exon 16-exon 9
PA9 Pilocytic astrocytoma I Cerebellum F 2 KIAA1549-BRAF exon 16-exon 11
PA10 Pilocytic astrocytoma I Cerebellum M 2 KIAA1549-BRAF exon 16-exon 9
PA11 Pilocytic astrocytoma I Cerebellum M 6 KIAA1549-BRAF exon 16-exon 9
PA12 Pilocytic astrocytoma I Cerebellum F 11 KIAA1549-BRAF exon 15-exon 9
PA13 Pilocytic astrocytoma I Posterior fossa M 4 KIAA1549-BRAF exon 16-exon 9
PA14 Pilocytic astrocytoma I Posterior fossa F 6 KIAA1549-BRAF exon 16-exon 9
PA15 Pilocytic astrocytoma I Posterior fossa M 9 KIAA1549-BRAF exon 16-exon 9
DA1 Diffuse astrocytoma II Temporal lobe F 12 No BRAFV600E
DA2 Diffuse astrocytoma II Unknown F 14 No BRAFV600E
DA3 Diffuse astrocytoma II Occipital lobe M 4 nd
DA4 * Diffuse astrocytoma II Unknown M 17 BRAFV600E present
AA1 Anaplastic astrocytoma III Conus medullaris M 15 nd
AA2 Anaplastic astrocytoma III Temporal lobe F 3 No BRAFV600E
AA3 * Anaplastic astrocytoma III Unknown F 11 No BRAFV600E
GBM1 Glioblastoma IV Frontal lobe F 15 No BRAFV600E
GBM2 Glioblastoma IV Temporoparietal M 10 No BRAFV600E
GBM3 Glioblastoma IV Brainstem F 4 nd
GBM4 Glioblastoma IV Left frontal lobe F 10 No BRAFV600E
GBM5 Glioblastoma IV Spinal cord F 7 nd
E1 Ependymoma III Posterior fossa M 4
E2 Ependymoma III Parietal lobe F 6
E3 Ependymoma II Posterior fossa F 2
E4 Ependymoma III Posterior fossa F 2
E5 Ependymoma II Temporal lobe M 12
E6 Ependymoma III Posterior fossa M 6
E7 Ependymoma III Posterior fossa M 2
E8 Ependymoma II Supratentorial (frontal) M 14
E9 Ependymoma II Posterior fossa M 3
E10 Ependymoma II Posterior fossa M 4
E11 Ependymoma III Posterior fossa F nd
E12 Ependymoma III Fourth ventricle M 1
E13 Ependymoma II Spinal seed F 6
E14 Ependymoma III Posterior fossa F 6
M1 Medulloblastoma IV Posterior fossa M 4
M2 Medulloblastoma IV Posterior fossa M 1
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to miR-423-3p and fold change calculated relative to the
average expression in adult cerebellum and frontal lobe
(BioChain, A508112 and B210079 respectively). Differential
expression was validated for miR-542-3p, miR-503, miR-
146a, miR-34a, miR-155, miR-124*, miR-129 and miR-
129*. TargetScan Release 6.2 (http://www.targetscan.org)
was used to search for predicted targets of microRNAs of
interest. MicroRNAs are named using the “miR’ prefix and
a unique identifying number which is assigned sequentially
[2]. Identical or very similar miRNA sequences within a
Table 1 Pediatric tumor cohorts (Continued)
M3 Medulloblastoma IV Posterior fossa F 6 months
M4 Medulloblastoma IV Posterior fossa M 7
M5 Medulloblastoma IV Posterior fossa M 3
M6 Medulloblastoma IV Posterior fossa M 9
M7 Medulloblastoma IV Posterior fossa M 7
M8 Medulloblastoma IV Posterior fossa M 9
M9 Medulloblastoma IV Posterior fossa M 4
M10 * Medulloblastoma IV Posterior fossa F 5
R1 Atypical Rhabdoid IV Brainstem M 1
R2 Atypical Rhabdoid IV Posterior fossa F 7 months
R3 Atypical Rhabdoid IV Supratentorial F 2
R4 Atypical Rhabdoid IV Posterior fossa M 9 months
R5 Atypical Rhabdoid IV Posterior fossa F 2 months
P1 Choroid Plexus Papilloma I Intraventricular (frontal lateral ventricle) M 10 months
P2 Choroid Plexus Papilloma I Posterior fossa M 1
P3 Choroid Plexus Papilloma I Left lateral ventricle M 3
P4 Choroid Plexus Papilloma I Unknown F nd
AC1 Adult control cerebellum Cerebellum M 22
AC2 Adult control frontal lobe Frontal lobe M 41
AC3 Adult control cerebellum Cerebellum M 21
AC4 Adult control cerebellum Cerebellum M 26
AC5 Adult control frontal lobe Frontal lobe M 82
AC6 Adult control frontal lobe Frontal lobe M 25
AC7 Adult control frontal lobe Frontal lobe M 27
b.
PA16 Pilocytic astrocytoma I Posterior fossa M 9 nd
PA17 Pilocytic astrocytoma I Posterior fossa M 12 nd
PA18 Pilocytic astrocytoma I Suprasellar M 3 KIAA1549-BRAF exon 15-exon 9
PA19 Pilocytic astrocytoma I 3rd ventricle M 16 nd
PA20 Pilocytic astrocytoma I Brain stem F 3 KIAA1549-BRAF exon 15-exon 9
PA21 Pilocytic astrocytoma I Posterior fossa F 4 KIAA1549-BRAF exon 16-exon 9
PA22 Pilocytic astrocytoma I Posterior fossa M 16 KIAA1549-BRAF exon 16-exon 9
PA23 Pilocytic astrocytoma I Posterior fossa F 2 KIAA1549-BRAF exon 16-exon 11
PA24 Pilocytic astrocytoma I Posterior fossa F 12 KIAA1549-BRAF exon 16-exon 9
GBM6 Glioblastoma IV Midbrain/Thalamus F 14 -
GBM7 Glioblastoma IV Occipital lobe M 4 months -
GBM8 Glioblastoma IV Thalamic/intraventriclar F 10 -
GBM9 Glioblastoma II Thalamic M 15 -
(a) Test cohort analysed using Illumina MicroRNA Expression Arrays (MI-v2) and Illumina HumanHT-12_v3 Beadchip system, with the exception of samples marked
with an asterisk (*), that were used for validation only
(b) Validation cohort used for confirmation of differentially expressed microRNAs and genes. Annotation: − negative, nd not determined
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species can be given the same number, with their genes
distinguished by a letter and/or numerical suffixes (e.g.
miR-450a and miR-450b are slightly different in sequence,
whereas those of miR-450a-1 and miR-450a-2 are identi-
cal). Some miRNA hairpin precursors give rise to two ex-
cised miRNAs, one from each arm. Previous annotations
used the nomenclature miR-124 and miR-124* for the
guide and passenger strand respectively, and some of these
names were included in our Illumina MicroRNA Expres-
sion Arrays (MI-v2). However, the mature sequences de-
rived from both arms of the hairpin may be biologically
functional, so current nomenclature uses miR-542-5p and
miR-542-3p to designate miRNAs from the ‘5’ and ‘3’ arms
respectively, [18, 29].
RT-qPCR
PCR primers were designed using Primer 3 software
(http://frodo.wi.mit.edu/primer3/) (Additional file 5:
Table S5). RT-qPCR was used to quantify the levels of
mRNA expression for selected genes, using SYBR
Green JumpStart Taq ReadyMix kit (Sigma-Aldrich),
50 ng cDNA, and 0.1 μM primers in a reaction volume
of 20 μl. Assays were run on an ABI 7500 Real Time
PCR System (ABI). PCR analyses were conducted in
triplicate for each sample and melting curves analyzed
for correct product size. Control genes TBP and CREB1
were tested for stability over all tumors, and TBP se-
lected as the most stable endogenous control. There-
fore, all samples were normalized to TBP and fold
change calculated relative to the average expression in
adult cerebellum (BioChain, A508112), and frontal lobe
(BioChain B210079). Relative quantification was calcu-
lated using the 2-ddCt method [35].
Results
Characterization of the pediatric brain tumor cohort
We first examined microRNA and gene expression in
the test tumor cohort that consisted of a papillary glio-
neuronal tumor (n = 1), pilocytic astrocytomas (n = 14),
diffuse astrocytomas (n = 3), anaplastic astrocytomas
(n = 2), glioblastomas (n = 5), atypical teratoid rhabdoid
tumors (AT/RT) (n = 5), medulloblastomas (n = 9),
ependymomas (n = 14) and choroid plexus papillomas
(n = 4), total = 57 samples (Table 1a). Differential micro-
RNA expression across the averaged tumor groups was cal-
culated to obtain fold changes compared to normal adult
brain controls (FDR < 0.05, Additional file 3: Table S3).
The number of up- and down-regulated microRNAs for
each tumor type is shown in Table 2. Unsupervised hier-
archical clustering (Euclidean method) of microRNAs
clustered the tumors by pathology in the low-grade tu-
mors, and showed higher-grade tumors to be more widely
distributed (Fig. 1a). A similar pattern was also found
using gene expression data (Additional file 2: Table S2),
with higher-grade tumors showing greater heterogeneity
than low-grade tumors (Fig. 1b). Following initial com-
parison with other tumor types, microRNA profiles were
then investigated in detail in pilocytic astrocytomas, all of
which contained the KIAA1549:BRAF gene fusion.
MicroRNA profile and the predicted targeted pathways in
Pilocytic Astrocytomas
Profiles from pilocytic astrocytomas were compared with
combined adult brain controls, and also with normal adult
cerebellum, since this subset of tumors were all located in
the cerebellum (Additional file 3: Table S3). Up- and
down-regulated microRNAs compared to normal adult
cerebellum are shown in Table 3. Amongst the top up-
regulated microRNAs was a cluster located on Xq26.3,
consisting of miR-542-5p, miR-542-3p, miR-503, mir-450a
and miR-450b-5p (Fig. 2). The results were not gender-
biased. Other top up-regulated microRNAs included miR-
224, miR-146a, miR-34a and the miR-106a ~miR-363
cluster (Table 3).
All the pilocytic astrocytomas used in the test cohort
contain the KIAA1549-BRAF fusion that activates the
ERK/MAPK pathway. Analysis of up-regulated micro-
RNAs using TargetScan revealed several predicted tar-
gets to be regulators of the MAPK pathway. These
included miR-155, which targets KRAS, miR-34a, which
targets MAP2K1 (MEK1), and miR-503, which targets
MAPK1 (ERK1) (Fig. 3). Other up-regulated microRNAs,
including MiR-450b, miR-542-3p and miR-155, are all
predicted to target ETS1, MYC and FOS, which are reg-
ulated by MAPK pathway components. In addition, the
up-regulated microRNAs, miR-155, miR-199a, miR-21
and miR-146a (Fig. 4a), target genes within the NF-κB
network (Figs. 3). Analysis of brain-specific microRNAs
[49] showed no significant differences in expression in
Table 2 Number of differentially expressed microRNAs in
pediatric brain tumors compared to normal adult brain
Pathology n Regulation Total
Up Down
Pilocytic astrocytoma 14 42 49 91
Pilocytic astrocytomaa 14 27 33 60
Diffuse astrocytoma 3 1 2 3
Anaplastic astrocytoma 2 6 8 14
Glioblastoma 5 0 5 5
Ependymoma 14 60 75 135
Medulloblastoma 9 25 35 60
Medulloblastomaa 9 10 29 39
Atypical Teratoid/Rhabdoid tumor 5 15 17 32
Choroid plexus papilloma 4 47 63 110
aPilocytic astrocytomas and medullobastomas were also compared to normal
adult cerebellum. Fold change > 2 with a FDR corrected p-value < 0.05
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pilocytic astrocytomas, apart from down-regulation of
miR-218. However, the majority of pilocytic astrocytomas
showed low expression of neuronal-specific microRNAs,
miR-129, miR-124 and miR-128 [50, 51] (Additional file 3:
Table S3).
Oncogene-induced senescence is associated with acti-
vation of an inflammatory transcriptome [31], and since
senescence markers have been identified in pilocytic astro-
cytomas, we examined expression levels of microRNAs and
genes known to be associated with senescence. MiR-146a
was amongst the top up-regulated microRNAs in pilocytic
astrocytomas, and is known to modulate senescence-asso-
ciated inflammatory mediators (Fig. 4a) [4]. Further-
more, CDKN1A (p21) and CDKN2A (p16) were found
to be up-regulated, together with the major transcrip-
tional inducers of senescence-associated secretory
phenotype (SASP), IGFBP7 and TIMP1 (Fig. 4b), as
well as CEBPB, TIMP2, TIMP3, AXL and other insulin-
like growth factor (IGF)-binding proteins that stimulate
inflammation, including IGFBP2, IGFBP3, IGFBP4 and
IGFBP5 (Additional file 4: Table S4).
Ingenuity Pathway Analysis was used to compare gene
expression data between pilocytic astrocytomas and nor-
mal adult cerebellum. The top canonical pathways show-
ing significant up-regulation included Antigen Presentation
Pathway, Graft-versus-Host Disease Signaling, Type I Dia-
betes Mellitus Signaling, Hepatic Fibrosis/Hepatic Stellate
Cell Activation and Dendritic Cell Maturation. Analysis of
the predicted activation state of up-stream transcription
factors showed 70 factors predicted as ‘activated’ and 28
predicted as ‘inhibited’ (p < 0.05, activation z-score > 2.0)
(Additional file 6: Table S6a, b). Predicted ‘activated’ tran-
scription factors included NF-kB complex, TP53, IRF7,
CEBPB, JUN, RELA and CEBPA, whilst predicted ‘inhib-
ited’ transcription factors included TRIM24, MYC, MYCN,
estrogen receptor and RB.
Fig. 1 Hierarchical clustering of microRNA and mRNA expression stratifies tumor subgroups. Unsupervised hierarchal clustering (Euclidean method)
was performed on (a) microRNA and (b) mRNA expression data. Tumors represented as: PA-pilocytic astrocytoma, PGNT-papillary glioneuronal tumor,
DA-diffuse astrocytoma, AA-anaplastic astrocytoma, GBM-glioblastoma, E-ependymoma, M-medulloblastoma, R-atypical rhabdoid tumor, P-choroid
plexus papilloma and AC1, AC3, AC4-adult control cerebellum and AC2, AC5, AC6, AC7-adult control frontal lobe. nd – not determined
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Using TaqMan assays and Real Time qRT-PCR, we
confirmed the differential expression of a set of micro-
RNAs and genes in a selection of the test tumor cohort,
as well as 13 tumors from the validation tumor cohort
(Additional file 7: Figure S1 and Additional file 8: Figure
S2). We confirmed up-regulation of miR-34a, miR-146a,
miR-542-3p, miR-503 and miR-155 and low expression
of neuronal microRNAs miR-124*, miR-129 and miR-
129* (Additional file 7: Figure S1). Up-regulation of the
senescence factors IGFBP7, CDKN2A (p16), IL6, IL8,
CDKN1A (p21) and down-regulation of CTCF was also
confirmed (Additional file 8: Figure S2).
Discussion
To gain a comprehensive understanding of tumorigen-
esis, it is critical to integrate findings on factors that
regulate the transcriptome, such as microRNAs, with
genomic analysis. This is especially pertinent in the case
of pediatric CNS tumors, which have fewer mutational
events than their adult counterparts [48, 54]. Micro-
RNAs are highly regulated and have essential functions
in brain development [23, 30], and certain microRNAs
are enriched or specifically expressed in the adult brain
[49]. Here, we profiled microRNA and gene expression in
a cohort of pediatric brain tumors, and then focused on
the potential role of microRNAs in pilocytic astrocytomas.
Table 3 The top deregulated microRNAs in pilocytic
astrocytoma compared to normal adult cerebellum
TargetID p (Corr) FC Log FC
a.
hsa-miR-224 0.00632 10.09 3.33
hsa-miR-542-5p 0.00558 9.69 3.28
hsa-miR-542-3p 0.02366 7.51 2.91
hsa-miR-450b-5p 0.00285 6.89 2.78
hsa-miR-503 0.00120 6.80 2.76
hsa-miR-450a 0.01211 6.67 2.74
hsa-miR-886-5p 0.00551 6.17 2.62
hsa-miR-767-5p 0.00002 4.94 2.31
HS_29 0.01811 4.41 2.14
hsa-miR-708 0.02645 3.92 1.97
hsa-miR-146a 0.01076 3.84 1.94
hsa-miR-34a 0.00268 3.13 1.65
solexa-539-2056 0.04379 3.03 1.60
hsa-miR-335* 0.00486 2.81 1.49
hsa-miR-18b 0.04529 2.79 1.48
hsa-miR-452* 0.00000 2.58 1.37
hsa-miR-18a 0.00441 2.56 1.36
hsa-miR-199a*:9.1 0.03622 2.56 1.36
hsa-miR-574-5p 0.00000 2.39 1.26
hsa-miR-296-3p 0.02907 2.36 1.24
hsa-miR-155 0.01372 2.33 1.22
hsa-miR-24-2* 0.00000 2.33 1.22
hsa-miR-106a 0.00149 2.32 1.21
hsa-miR-21* 0.00073 2.22 1.15
HS_262.1 0.01814 2.16 1.11
hsa-miR-363 0.01021 2.07 1.05
hsa-miR-371-3p 0.00002 2.03 1.02
b.
hsa-miR-129-3p 0.00062 −44.25 −5.47
hsa-miR-129* 0.00000 −27.08 −4.76
hsa-miR-1224-5p 0.00515 −16.54 −4.05
hsa-miR-124a:9.1 0.00357 −15.84 −3.99
hsa-miR-326 0.01508 −12.16 −3.60
hsa-miR-124 0.00073 −9.66 −3.27
hsa-miR-204 0.00140 −9.65 −3.27
hsa-miR-1296 0.00000 −6.94 −2.80
hsa-miR-885-5p 0.00006 −6.76 −2.76
hsa-miR-128a:9.1 0.00149 −5.78 −2.53
hsa-miR-218 0.00504 −5.72 −2.52
hsa-miR-133b 0.00000 −5.57 −2.48
hsa-miR-874 0.00013 −5.52 −2.46
hsa-miR-769-3p 0.02429 −4.96 −2.31
Table 3 The top deregulated microRNAs in pilocytic
astrocytoma compared to normal adult cerebellum (Continued)
hsa-miR-485-3p 0.01589 −4.70 −2.23
hsa-miR-128b:9.1 0.00049 −4.68 −2.23
HS_182.1 0.00140 −4.45 −2.15
hsa-miR-107 0.00002 −4.38 −2.13
hsa-miR-383 0.00175 −4.36 −2.12
hsa-miR-656 0.00825 −4.35 −2.12
hsa-miR-124* 0.03622 −4.14 −2.05
hsa-miR-584 0.00130 −3.61 −1.85
hsa-miR-7 0.00108 −3.40 −1.77
hsa-miR-548k 0.01014 −3.39 −1.76
hsa-miR-1237 0.00149 −3.21 −1.68
hsa-miR-299-5p 0.01076 −3.20 −1.68
hsa-miR-1179 0.01508 −2.92 −1.55
hsa-miR-487b 0.03622 −2.75 −1.46
HS_231 0.00367 −2.73 −1.45
hsa-miR-329 0.00101 −2.47 −1.30
hsa-miR-154* 0.00566 −2.47 −1.30
hsa-miR-889 0.01811 −2.15 −1.11
hsa-miR-135a 0.02645 −2.06 −1.04
(a) Up-regulated microRNAs and (b) down-regulated microRNAs. Differential
expression was defined as fold change (FC) > 2 with FDR corrected (Benjamini
Hochberg) p-values <0.05
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The mitogen-activated protein kinase (MAPK) signal-
ing cascade is the main molecular pathway that is
deregulated in pilocytic astrocytomas [56]. BRAF-gene
fusions and, in rare cases, BRAF V600E mutations give
rise to constitutively active BRAF, which in turn activates
the MAPK pathway. Furthermore, BRAF activation has
been shown to cause oncogene-induced senescence in
vitro [24, 42]. Hence, we obtained gene expression
profiles for pilocytic astrocytomas in order to identify
any senescent or inflammatory markers that may ex-
plain the less aggressive nature of these tumors. Senes-
cence is accompanied by increased secretion of factors
involved in senescent signaling. In pilocytic astrocyto-
mas, we observed up-regulation of IGFBP7 and CEBPB,
both of which are major transcriptional inducers of
SASP-related genes [16]. In addition, we observed up-
Fig. 2 Expression of a cluster of microRNAs on Xq26.3 in pilocytic astrocytomas. (a) Map of microRNA genes showing up-regulated microRNAs
transcribed in the same direction. (b) Illumina MicroRNA Expression array (MI-v2) data showing up-regulation of miR-503, miR-542-3p, miR-542-5p,
miR-450a and miR-450b-5p in pilocytic astrocytoma compared to normal brain controls. The Illumina probe miR-450a contains the seed sequence
present in both miR-450a-1 and miR-450a-2
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regulation of IL1B, which has been shown to be a
SASP-associated protein [10]. Our gene expression profil-
ing of pilocytic astrocytomas also revealed up-regulation
of many genes involved in immune function. This was
supported by pathway analysis, which showed that pilocy-
tic astrocytomas exhibit a strong immune and inflamma-
tory response.
There is accumulating evidence for a role for certain
microRNAs in senescence [1, 17, 19]. The miR-424-
miR-503 polycistron, as well as miR-450, miR-542-3p
and miR-450b-5p are suggested to play a role in repli-
cative senescence and cellular aging in fibroblasts [6].
MiR-424 and miR-503 can induce G1 arrest in THP-1
cells [14] and may limit proliferation in pilocytic astro-
cytomas. Recently, expression of miR-542-5p, which is
repressed in MYC-amplified neuroblastomas was shown
to be positively correlated with survival [46]. Interestingly,
CTCF, a predicted target of miR-542-3p, is down-regulated
in pilocytic astrocytoma, and a recent investigation into
the higher-order chromatin structure of the INK4/ARF
locus in senescent cells, has revealed down-regulation of
CTCF in oncogene-induced senescent cells [20].
Predicted targets of differentially regulated micro-
RNAs frequently included components of the ERK/
MAPK and NF-κB signaling pathways (Fig. 3). MiR-503
and miR155 are predicted to target components of the
ERK/MAPK pathway, as well as miR-34a which can in-
duce cell cycle arrest by targeting Notch ligand delta-
like 1, a component of NOTCH signaling [11], and cell
cycle regulators CCND1 and CDK6 [52]. The same
microRNAs are also predicted to target components of
NF-κB signaling. MiR-155 has many target genes in-
cluding IKKε, suggesting a role in the immune response
[53]. In ovarian tumors, miR-199a negatively regulates
IKKβ expression to reduce NF-κB activity [8]. NF-κB is
reported to be a direct transcriptional regulator of miR-
224 [47] and we observe up-regulation of the miR-224
in our pilocytic astrocytomas. In addition, miR-224 has
been shown to target the tumor suppressor RKIP in hu-
man breast cancer [22]. MiR-146a, which is induced by
inflammation in the presence of NF-κB and IL1 recep-
tor signaling to modulate senescent mediators, is up-
regulated specifically in pilocytic astrocytomas [4]. In
fibroblasts, miR-146a/b down-regulates IRAK1 to reduce
Fig. 3 Model showing the interplay of microRNAs in senescence, proliferation and inflammation. MicroRNAs provide negative feedback of the RB
pathway, the MAPK pathway and the NF-κΒ network. MiR-34a and miR-503 are predicted to target CCND1 and CDK4 to limit cell proliferation via
the RB pathway. MiR-155 is predicted to target KRAS, miR-34a is predicted to target MEK1, whilst down stream targets of the MAPK pathway include
SPRED1 (a predicted target of miR-503), SPRY1, SPRY2 and SPRY4 (predicted targets of miR-450b-5p) and FOS and ETS1 (predicted targets of miR-155).
MicroRNAs that act as effectors and regulators of NF-κB include miR-146a, miR-155, miR-199a and miR-21. MiR-146a, miR-224 and miR-155 are
predicted to target senescenceassociated genes and thus to regulate levels of inflammation
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IL6 and IL8 secretion in an elegant feedback loop [4]. The
expression of miR-146a is a late manifestation of senes-
cence [43] and it is possible that the few pilocytic
astrocytomas that do not show elevated expression of
miR-146a have not reached a “mature” level of the sen-
escent phenotype.
Brain tissues are composed of multiple neuronal, astro-
glial, microglial and other cell types, so the relative contri-
butions of each brain cell type to the overall microRNA
and gene expression profiles remain to be elucidated.
MiR-146a and miR-155 are expressed by activated
microglia and astroglial cells in culture [7, 34, 44]. There-
fore, it is possible that some of our up-regulated micro-
RNAs could also potentially represent the proliferating
microglia that are reported to be present in pilocytic as-
trocytomas [28]. A recent study has demonstrated that
increased activation of RAS/ERK signaling in neocor-
tical progenitors produced a NEUROG2-ASCL1 switch,
which promotes glial fate [55]. This developmental
neurogenic to gliogenic switch in transcription factor
expression is supported in studies of RAS-driven gli-
oma formation from neural stem cells [25, 40]. In a
Fig. 4 Expression of microRNAs and genes involved in senescence in pilocytic astrocytomas. (a) Illumina MicroRNA Expression array (MI-v2) data
showing miR-146a and miR-155 are up-regulated in the majority of pilocytic astrocytomas and (b) Illumina HumanHT-12_v3 expression array data
showing a higher level of expression for CDKN2A, IGFBP7 and TIMP1 in pilocytic astrocytomas compared to normal brain controls
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recently developed mouse model of gliomagenesis, high
RAS/ERK levels were found to modify Ascl1 activity
giving rise to glial tumors [33], and we observe clear
up-regulation of ASCL1 in the pilocytic astrocytomas
(Additional file 4: Table S4). These authors demon-
strated that whilst RAS/ERK signaling is critical for
neurodevelopment, ERK is the key effector as it phos-
phorylates the ASCL1 protein resulting in its gliogenic
effect. Hence, enhanced RAS/ERK signaling in the pilo-
cytic astrocytomas by activated BRAF may have trig-
gered a gliogenic switch, and this is reflected in the
expression of microRNAs that are usually observed in
astroglial cells.
Conclusions
In summary, we show that pilocytic astrocytomas differ-
entially express microRNAs that target genes that en-
code regulators of the MAPK and NF-κB pathways, as
well as genes that are markers of inflammation. These
microRNAs and the post-translational regulation of their
gene targets may therefore play a role in the unique
phenotype of pilocytic astrocytomas.
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